Despite another delay, Intercept says its NASH drug remains on track

The coronavirus outbreak, though, adds more uncertainty to what will be a closely watched regulatory review of Intercept's therapy.

Despite another delay, Intercept says its NASH drug remains on track
The coronavirus outbreak, though, adds more uncertainty to what will be a closely watched regulatory review of Intercept's therapy.